Molluscum Contagiosum Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum Contagiosum
WEST CHESTER, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - January 3, 2019 Category: Pharmaceuticals Source Type: clinical trials
A Study to Evaluate the Safety and Efficacy of SB206 in Children and Adolescents With Molluscum Contagiosum
Condition: Molluscum Contagiosum Interventions: Drug: SB206 4%; Drug: SB206 8%; Drug: SB206 12%; Drug: Placebo Sponsors: Novan, Inc.; Premier Research Group plc Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 16, 2018 Category: Research Source Type: clinical trials
